Search

Your search keyword '"Cignetti A"' showing total 7 results
Start Over Author "Cignetti A" Journal blood cancer journal
7 results on '"Cignetti A"'

1. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program

Author

Guolo, Fabio, Fianchi, Luana, Minetto, Paola, Clavio, Marino, Gottardi, Michele, Galimberti, Sara, Rizzuto, Giuliana, Rondoni, Michela, Bertani, Giambattista, Dargenio, Michela, Bilio, Atto, Scappini, Barbara, Zappasodi, Patrizia, Scattolin, Anna Maria, Grimaldi, Francesco, Pietrantuono, Giuseppe, Musto, Pellegrino, Cerrano, Marco, D’Ardia, Stefano, Audisio, Ernesta, Cignetti, Alessandro, Pasciolla, Crescenza, Pavesi, Francesca, Candoni, Anna, Gurreri, Carmela, Morselli, Monica, Alati, Caterina, Fracchiolla, Nicola, Rossi, Giovanni, Caizzi, Manuela, Carnevale-Schianca, Fabrizio, Tafuri, Agostino, Rossi, Giuseppe, Ferrara, Felicetto, Pagano, Livio, and Lemoli, Roberto Massimo

Published
2020
Full Text
View/download PDF

2. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program

Author

Paola Minetto, Carmela Gurreri, Fabio Guolo, Anna Candoni, Giovanni Rossi, Giambattista Bertani, Marco Cerrano, Patrizia Zappasodi, Francesco Grimaldi, Atto Bilio, Anna Maria Scattolin, Barbara Scappini, Pellegrino Musto, Marino Clavio, Agostino Tafuri, Livio Pagano, Crescenza Pasciolla, Giuseppe Pietrantuono, Monica Morselli, Alessandro Cignetti, Roberto M. Lemoli, Sara Galimberti, Ernesta Audisio, Nicola Stefano Fracchiolla, Fabrizio Carnevale-Schianca, Felicetto Ferrara, Stefano D'Ardia, Giuseppe Rossi, Francesca Pavesi, Manuela Caizzi, Michele Gottardi, Luana Fianchi, Giuliana Rizzuto, Michela Rondoni, Michela Dargenio, Caterina Alati, Guolo, F., Fianchi, L., Minetto, P., Clavio, M., Gottardi, M., Galimberti, S., Rizzuto, G., Rondoni, M., Bertani, G., Dargenio, M., Bilio, A., Scappini, B., Zappasodi, P., Scattolin, A. M., Grimaldi, F., Pietrantuono, G., Musto, P., Cerrano, M., D'Ardia, S., Audisio, E., Cignetti, A., Pasciolla, C., Pavesi, F., Candoni, A., Gurreri, C., Morselli, M., Alati, C., Fracchiolla, N., Rossi, G., Caizzi, M., Carnevale-Schianca, F., Tafuri, A., Ferrara, F., Pagano, L., and Lemoli, R. M.

Subjects
Compassionate Use Trials, Male, medicine.medical_specialty, medicine.medical_treatment, neoplasms, acute myeloid - leukemia, minimal residual disease, myelodysplastic syndrome, molar ratiotherapy, neoplasms, cytarabine, daunorubicin, Drug development, Hematopoietic stem cell transplantation, Gene mutation, lcsh:RC254-282, Disease-Free Survival, Article, molar ratiotherapy, Internal medicine, Medicine, Secondary Acute Myeloid Leukemia, Humans, Cumulative incidence, Survival rate, Aged, Leukemia, business.industry, Mortality rate, Daunorubicin, Cytarabine, Hematopoietic Stem Cell Transplantation, Neoplasms, Second Primary, Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Allografts, Transplantation, Survival Rate, Settore MED/15 - MALATTIE DEL SANGUE, Regimen, Leukemia, Myeloid, Acute, Combination drug therapy, Oncology, Italy, Female, business, Follow-Up Studies
Abstract

Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and allogeneic stem cell transplantation (HSCT). We evaluated toxicity and efficacy of CPX-351 in 71 elderly patients (median age 66 years) with sAML enrolled in the Italian Named (Compassionate) Use Program. Sixty days treatment-related mortality was 7% (5/71). The response rate at the end of treatment was: CR/CRi in 50/71 patients (70.4%), PR in 6/71 (8.5%), and NR in 10/71 (19.7%). After a median follow-up of 11 months relapse was observed in 10/50 patients (20%) and 12 months cumulative incidence of relapse (CIR) was 23.6%. Median duration of response was not reached. In competing risk analysis, CIR was reduced when HSCT was performed in first CR (12 months CIR of 5% and 37.4%, respectively, for patients receiving (=20) or not (=30) HSCT, p = 0.012). Twelve-months OS was 68.6% (median not reached). In landmark analysis, HSCT in CR1 was the only significant predictor of longer survival (12 months OS of 100 and 70.5%, for patients undergoing or not HSCT in CR1, respectively, p = 0.011). In conclusion, we extend to a real-life setting, the notion that CPX is an effective regimen for high risk AML patients and may improve the results of HSCT.

Published
2020

3. Erratum: Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups

Author

Riva, L, primary, Ronchini, C, additional, Bodini, M, additional, Lo-Coco, F, additional, Lavorgna, S, additional, Ottone, T, additional, Martinelli, G, additional, Iacobucci, I, additional, Tarella, C, additional, Cignetti, A, additional, Volorio, S, additional, Bernard, L, additional, Russo, A, additional, Melloni, G E M, additional, Luzi, L, additional, Alcalay, M, additional, Dellino, G I, additional, and Pelicci, P G, additional

Published
2014
Full Text
View/download PDF

4. Erratum: Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups

Author

Giorgio E. M. Melloni, Alessandro Cignetti, Sara Volorio, P. G. Pelicci, Ilaria Iacobucci, F Lo Coco, Corrado Tarella, Lucilla Luzi, Myriam Alcalay, Gaetano Ivan Dellino, Tiziana Ottone, Chiara Ronchini, Serena Lavorgna, Margherita Bodini, Loris Bernard, Laura Riva, Anna Di Russo, and Giovanni Martinelli

Subjects
Blood cancer, Oncology, business.industry, Immunology, Cancer research, Myeloid leukemia, Medicine, Hematology, business
Published
2014
Full Text
View/download PDF

5. Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups

Author

Riva, L, primary, Ronchini, C, additional, Bodini, M, additional, Lo-Coco, F, additional, Lavorgna, S, additional, Ottone, T, additional, Martinelli, G, additional, Iacobucci, I, additional, Tarella, C, additional, Cignetti, A, additional, Volorio, S, additional, Bernard, L, additional, Russo, A, additional, Melloni, G E M, additional, Luzi, L, additional, Alcalay, M, additional, Dellino, G I, additional, and Pelicci, P G, additional

Published
2013
Full Text
View/download PDF

6. Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups

Author

Giorgio E. M. Melloni, Margherita Bodini, Loris Bernard, Alessandro Cignetti, Laura Riva, Sara Volorio, Giovanni Martinelli, Anna Di Russo, Corrado Tarella, Myriam Alcalay, Gaetano Ivan Dellino, Chiara Ronchini, Ilaria Iacobucci, Lucilla Luzi, Serena Lavorgna, Pier Giuseppe Pelicci, Tiziana Ottone, and Francesco Lo-Coco

Subjects
Blood cancer, Oncology, business.industry, MEDLINE, Myeloid leukemia, Medicine, Hematology, Erratum, business, Bioinformatics, Settore MED/15 - Malattie del Sangue, Letter to the Editor
Abstract

Correction to: Blood Cancer Journal (2013) 3, e147; doi: 10.1038/bcj.2013.46; published online 13 September 2013

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results